ICCM
IceCure Medical
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
Consensus Rating "Strong Buy"
MACD Death Cross
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ICCM
Icecure Medical Ltd.
A medical device company that developing advance treatment for cancerous tumors
Healthcare Equipment and Supplies
Invalid Date
08/26/2021
NASDAQ Stock Exchange
64
12-31
Common stock
7 HaEshel St., PO Box 3163, Caesarea, 3079504 Israel
Focus on the research, development and marketing of cryoablation systems and technologies for the treatment of tumors with liquid nitrogen or LN 2.
IceCure Medical Ltd., was incorporated in Israel in 2006. The Company is a commercial-stage medical device company focused on the research, development and marketing of cryoablation systems and technologies for the treatment of tumors with liquid nitrogen or LN 2. Their proprietary cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in breast, lung, kidney, bone and other indications. Their industry-leading commercial cryoablation product is the ProSense system.
Earnings Call
Q1/2025
Estimate EPS-0.08
Actual EPS0.06
Estimate Revenue750.00K
Actual Revenue725.00K
IceCure Medical's Q1 2025: Key Contradictions in FDA Studies, Sales Strategies, and Team Expansion
May 28,2025 04:32
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ICCM has released its 2025 Q1 earnings. EPS was reported at 0.06, versus the expected -0.08, beating expectations. The chart below visualizes how ICCM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ICCM has released its 2025 Q1 earnings report, with revenue of 725.00K, reflecting a YoY change of -2.42%, and net profit of -3.59M, showing a YoY change of 0.58%. The Sankey diagram below clearly presents ICCM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
